A Clinical Trials to Evaluate the Efficacy and Safety of Tenofovir With and Without DWPUR001 in Patients With HBV
Status:
Unknown status
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The patient who meets the inclusion/exclusion criteria is assigned to Test1 group or Test 2
group or control group randomly.
All subjects take one pill of Viread® Tab. (Tenofovir Disoproxil Fumarate 300mg) once a day
for 48 weeks. At the same time, all randomized subjects take two pills of DWPUR001 or Placebo
of DWPUR001 twice a day for 48 weeks.